Hackettstown, NJ, United States of America

Matthew Michael Hamilton

This inventor holds 59 USPTO granted patents and 27 published patent applications, plus 4 CIPO patents and 20 EPO patents, primarily in Drug Discovery (CPC class C07D). Top assignees: Vertex Pharmaceuticals, Inc., The University of Texas System, Hoffmann-La Roche Inc.. Active years: 2008-2026.

USPTO Granted Patents = 59 (Patent Applications = 27)

% Patents Active = 71.2

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 20 (Patent Applications = 25)

Average Co-Inventor Count = 5.9

ph-index = 26

Forward Citations = 2,332(Granted Patents)

Forward Citations (Not Self Cited) = 2,062(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Hacketstown, NJ (US) (2011)
New Jersey, CA (US) (2011)
Hackettsown, NJ (US) (2012)
Wallingford, PA (US) (2014)
Hackettestown, NJ (US) (2017)
Gainesville, FL (US) (2014 - 2019)
Hackettstown, NJ (US) (2008 - 2022)
Missouri City, TX (US) (2014 - 2024)

Company Filing History:

26 out of 1,167

Vertex Pharmaceuticals, Inc.

patents

15 out of 5,622

The University of Texas System

patents

11 out of 5,011

Hoffmann-La Roche Inc.

patents

4. 3 out of 28

Madrigal Pharmaceuticals, Inc.

Via Pharmaceuticals, Inc.

patents

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

GLS1 Inhibitors

Integrin Antagonists

ABC Transporter Modulators

Receptor Interacting Protein Kinase

Tryptophan Dioxygenase

Stem Cell Differentiation

Chitosan Conjugates

Joint Kinematics

N-Alkyltriazole Compounds

Hepatocyte Differentiation

Pyrrolopyrazine Kinase

Talar Implant

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12565490 - Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease (2026-03-03),

2. 12286406 - Inhibitors of receptor interacting protein kinase I for the treatment of disease (2025-04-29),

3. 11958849 - GLS1 inhibitors for treating disease (2024-04-16),

4. 11753381 - Inhibitors of receptor interacting protein kinase I for the treatment of disease (2023-09-12),

5. 11718612 - Inhibitors of receptor interacting protein kinase I for the treatment of disease (2023-08-08),

6. 11713313 - GLS1 inhibitors for treating disease (2023-08-01),

7. 11690850 - Inhibitors of receptor interacting protein kinase I for the treatment of disease (2023-07-04),

8. 11491178 - Chitosan covalently linked with small molecule integrin antagonist for targeted delivery (2022-11-08),

9. 11370786 - GLS1 inhibitors for treating disease (2022-06-28),

10. 11173145 - Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase (2021-11-16),

11. 11084804 - Modulators of ATP-binding cassette transporters (2021-08-10),

12. 11046649 - Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase (2021-06-29),

13. 10766892 - GLS1 inhibitors for treating disease (2020-09-08),

14. 10738043 - GLS1 inhibitors for treating disease (2020-08-11),

15. 10626111 - Modulators of ATP-binding cassette transporters (2020-04-21),

Title: Matthew Michael Hamilton: A Pioneer in Pharmaceutical Innovations

Introduction

Matthew Michael Hamilton, based in Hackettstown, NJ, is a prominent inventor known for his significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 54 patents, he has been at the forefront of innovations targeting critical health challenges.

Latest Patents

Hamilton's latest patents focus on the development of inhibitors of receptor interacting protein kinase 1 (RIPK1) for the treatment of various diseases. He has disclosed compounds that inhibit RIPK1 along with pharmaceutical compositions and methodologies aimed at addressing RIPK1-mediated diseases. These include neurodegenerative disorders, inflammatory disorders, and cancers, showcasing his commitment to advancing medical science.

Career Highlights

Throughout his career, Matthew has worked with leading organizations, including Vertex Pharmaceuticals, Inc. and the University of Texas System. His work has significantly contributed to the understanding and treatment of complex diseases, making him a key figure in pharmaceutical innovation.

Collaborations

Hamilton has collaborated with esteemed colleagues, including Mark Thomas Miller and Peter D. J. Grootenhuis. These partnerships have fostered a collaborative environment that encourages groundbreaking research and development in the pharmaceutical sector.

Conclusion

Matthew Michael Hamilton stands out as a dedicated inventor whose work continues to influence medical treatments and therapeutic interventions. His innovations not only reflect his expertise but also contribute to the greater good, improving lives through advanced medical solutions.